Abeona Therapeutics Inc (ABEO)

2.18 +0.09  +4.31% NASDAQ Apr 6, 12:15 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
05/14/2020 10:00 EDT Misc Abeona Therapeutics Inc First Quarter Earnings Conference Call in 2020
05/14/2020 Earnings Abeona Therapeutics Inc First Quarter Earnings in 2020 Release
03/17/2020 10:00 EDT Misc Abeona Therapeutics Inc Fourth Quarter Earnings Conference Call for 2019
03/16/2020 Earnings Abeona Therapeutics Inc Fourth Quarter Earnings Results for 2019
03/16/2020 Misc Abeona Therapeutics Inc Annual Report for 2019
11/13/2019 10:00 EST Misc Abeona Therapeutics Inc Third Quarter Earnings Conference Call for 2019
11/12/2019 Earnings Abeona Therapeutics Inc Third Quarter Earnings Results for 2019
08/12/2019 10:00 EDT Misc Abeona Therapeutics Inc Second Quarter Earnings Conference Call in 2019
08/12/2019 Earnings Abeona Therapeutics Inc Second Quarter Earnings in 2019 Release
05/28/2019 10:00 EDT Misc Abeona Therapeutics Inc Annual General Meeting in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.abeonatherapeutics.com
  • Investor Relations URL: N/A
  • HQ State/Province: New York
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Value
  • Next Earnings Release: May. 14, 2020
  • Last Earnings Release: Mar. 16, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. The gene therapy involves the use of DNA as a potential therapy to treat a disease. The company's initial programs are focused on lysosomal storage diseases such as Mucopolysaccharidosis (MPS) IIIA and IIIB. It is also developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-50X for the treatment of retinal diseases.

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.